Showing results (571-580 of 689) with videos related to

Sort By:
Pageof 69
Lancet (London, England)|December 4, 2014
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialBrent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, et al.
The American Journal of Gastroenterology|June 18, 2021
Liver-Unrelated Comorbid Conditions Do Not Affect Cognitive Performance or Hepatic Encephalopathy Progression in CirrhosisChathur Acharya, Omar Nadhem, Jawaid Shaw, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 22, 2023
Machine-learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD-related liver fibrosisRong Fan, Ning Yu, Guanlin Li, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 28, 2014
Effects of obstructive sleep apnea on sleep quality, cognition, and driving performance in patients with cirrhosisJasmohan S Bajaj, Leroy R Thacker, David Leszczyszyn, et al.
JAMA|April 28, 2011
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trialJoel E Lavine, Jeffrey B Schwimmer, Mark L Van Natta, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 21, 2021
Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic ReviewJie Ning Yong, Wen Hui Lim, Cheng Han Ng, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 23, 2023
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b StudyRohit Loomba, Arun J Sanyal, Atsushi Nakajima, et al.
Nature Communications|June 23, 2026
The metabolic vulnerability index predicts outcomes in patients with metabolic dysfunction associated steatotic liver diseaseMohammad S Siddiqui, Mark L Van Natta, Margery A Connelly, et al.
JAMA Network Open|October 5, 2019
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver DiseaseDavid E Kleiner, Elizabeth M Brunt, Laura A Wilson, et al.
Digestive Diseases and Sciences|June 28, 2024
Sex and Race-Ethnic Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease: An Analysis of 40,166 IndividualsClarissa Elysia Fu, Margaret Teng, Daniel Tung, et al.
Pageof 69